| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Staidson (Beijing) BioPharmaceuticals Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥5.81 |
| 52 Week High | CN¥13.33 |
| 52 Week Low | CN¥5.44 |
| Beta | 0.42 |
| 11 Month Change | -0.51% |
| 3 Month Change | -14.18% |
| 1 Year Change | -41.67% |
| 33 Year Change | -47.85% |
| 5 Year Change | -50.00% |
| Change since IPO | -69.34% |
Recent News & Updates
Recent updates
Shareholder Returns
| 300204 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | 1.4% | -0.7% | -1.4% |
| 1Y | -41.7% | -22.5% | -18.4% |
Return vs Industry: 300204 underperformed the CN Biotechs industry which returned -22.5% over the past year.
Return vs Market: 300204 underperformed the CN Market which returned -18.4% over the past year.
Price Volatility
| 300204 volatility | |
|---|---|
| 300204 Average Weekly Movement | 7.9% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in CN Market | 10.0% |
| 10% least volatile stocks in CN Market | 4.2% |
Stable Share Price: 300204's share price has been volatile over the past 3 months.
Volatility Over Time: 300204's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 555 | Wang Chao | www.staidson.com |
Staidson (Beijing) BioPharmaceuticals Co., Ltd. primarily engages in the research and development, production, and marketing of therapeutic drugs in China. The company offers protein drugs, including therapeutic monoclonal antibody drugs; gene therapy/cell therapy drugs; and chemical drugs. It principally offers its products under the fields of nervous system related, infectious, gastrointestinal, urinary system, and autoimmune diseases.
Staidson (Beijing) BioPharmaceuticals Co., Ltd. Fundamentals Summary
| 300204 fundamental statistics | |
|---|---|
| Market cap | CN¥2.78b |
| Earnings (TTM) | -CN¥353.94m |
| Revenue (TTM) | CN¥394.14m |
6.8x
P/S Ratio-7.6x
P/E RatioIs 300204 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300204 income statement (TTM) | |
|---|---|
| Revenue | CN¥394.14m |
| Cost of Revenue | CN¥79.65m |
| Gross Profit | CN¥314.49m |
| Other Expenses | CN¥668.43m |
| Earnings | -CN¥353.94m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 27, 2024
| Earnings per share (EPS) | -0.74 |
| Gross Margin | 79.79% |
| Net Profit Margin | -89.80% |
| Debt/Equity Ratio | 2.8% |
How did 300204 perform over the long term?
See historical performance and comparison